## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Limited Waiver under 18 U.S.C. §208(b)(3)

## Steven Nissen, M.D.

Committees:	Endocrinologic & Metabolic Drugs and the Drug Safety and Risk
	Management Advisory Committees

Meeting Dates: July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive a limited waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Employer's Research Contracts/Grants	2 Competing Firms	Between \$100,001 and \$300,000 per year per firm
Employer's Research Grant	Competing Firm	Greater than \$300,000 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the limited waiver is not valid.

/s/

Signature of SGE

<u>7/5/07</u> Date